Poster: MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results — David A. Sallman (2022) | RDL Network
Poster: MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results
David A. Sallman, Monzr M. Al Malki, Adam Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua F. Zeidner, Guillermo Garcia‐Manero, Deepa Jeyakumar, Lin Gu, Anderson Tan, Mark P. Chao, Carol O’Hear, Indu Lal, Paresh Vyas, Naval Daver
David A. Sallman, Monzr M. Al Malki, Adam Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua F. Zeidner, Guillermo Garcia‐Manero, Deepa Jeyakumar, Lin Gu, Anderson Tan, Mark P. Chao, Carol O’Hear, Indu Lal, Paresh Vyas, Naval Daver
Chitra Hosing, Rima M. Saliba, Amin M. Alousi, Gheath Alatrash, Yosra Aljawai, Qaiser Bashir, Guanrong Chen, Warren Fingrut, Jin S. Im, Partow Kebriaei, David Marín, Yago Nieto, Anders Olson, Betül Oran, M. Qazilbash, Jeremy Ramdial, Neeraj Saini, Portia Smallbone, Samir Srour, Alexandre Bazinet, G. García-Manero, ,
Discussion(0)
No comments yet. Be the first to comment.